Why Triple Therapy Increases Pneumonia Risk
The increased pneumonia risk with LABA+LAMA+ICS triple therapy is specifically attributable to the inhaled corticosteroid (ICS) component, not the bronchodilators—this is a recognized class effect of ICS-containing therapies in COPD patients. 1
The ICS Component is the Culprit
The mechanism behind increased pneumonia risk relates directly to the immunosuppressive effects of inhaled corticosteroids on local pulmonary defenses. When ICS is deposited in the airways, it:
- Suppresses local immune responses in the respiratory tract
- Impairs mucociliary clearance mechanisms
- Reduces the ability to clear bacterial pathogens
- Creates an environment more susceptible to respiratory infections
Pneumonia is recognized as a class effect of all ICS-containing therapies in COPD, with no conclusive evidence of differences between specific ICS molecules. 1
Risk Magnitude and Clinical Context
The 2023 Canadian Thoracic Society guidelines provide critical context for understanding this risk 1:
- Number needed to harm: 33 patients treated for 1 year to cause one pneumonia
- Number needed to treat: 4 patients for 1 year to prevent one moderate-to-severe exacerbation
- This 8:1 benefit-to-harm ratio demonstrates that the exacerbation reduction benefits substantially outweigh pneumonia risks
The incidence of pneumonia is highest in individuals with severe and very severe COPD—ironically, these are precisely the patients who benefit most from ICS-containing regimens. 1
Evidence from Recent Studies
High-certainty evidence confirms the pneumonia signal:
- Triple therapy showed a 74% increased risk of pneumonia as a serious adverse event compared to LABA/LAMA alone (OR 1.74,95% CI 1.39-2.18) 2
- The IMPACT trial demonstrated a 53% higher risk of clinician-diagnosed pneumonia with triple therapy versus LABA/LAMA (HR 1.53,95% CI 1.22-1.92) 3
- Japanese population data showed even higher risk with 3.38-fold increased pneumonia odds (OR 3.38,95% CI 1.58-7.22) 4
Additional Risk Factors Beyond ICS
The guidelines emphasize that many other factors contribute to pneumonia risk in COPD patients beyond ICS use 1:
- Severity of airflow limitation (FEV1 < 50% predicted)
- History of prior pneumonia
- Advanced age
- Comorbidities
- Malnutrition
- Impaired baseline immune function
Clinical Decision-Making Algorithm
Despite the pneumonia risk, triple therapy remains indicated when:
- Patient has high exacerbation risk (≥2 moderate or ≥1 severe exacerbation in past year)
- Moderate-to-high symptom burden (CAT ≥10, mMRC ≥2)
- Impaired lung function (FEV1 < 80% predicted)
- Patient remains symptomatic on LABA/LAMA alone
The mortality benefit of triple therapy outweighs pneumonia risk in this population—triple therapy reduces all-cause mortality compared to LABA/LAMA (OR 0.70,95% CI 0.54-0.90) 2, and the ETHOS study demonstrated specific mortality benefits with moderate-dose ICS 1.
Important Caveats
- Higher ICS doses increase adverse effects without proportional benefit—moderate doses are preferred 1
- Stepping down from triple therapy is not recommended in high-risk patients, as ICS withdrawal increases exacerbation risk, particularly in those with eosinophils ≥300 cells/µL 1
- Monitor patients on triple therapy vigilantly for signs of respiratory infection, but do not withhold therapy based solely on pneumonia concerns in appropriate candidates 1
The pneumonia risk is real and quantifiable, but in properly selected patients (those at high exacerbation risk with significant symptoms), the benefits of triple therapy in reducing exacerbations, improving quality of life, and reducing mortality justify accepting this increased pneumonia risk.